遠大醫藥(00512.HK)全球創新產品STC3141獲中國藥監局批准開展II期臨床研究
遠大醫藥(00512.HK)公布,全資擁有附屬公司Grand Medical Pty Ltd.(一間集團在澳洲設立的創新藥研發中心)正在開發的用於重症領域的全球創新藥物STC3141,近日在中國獲藥監局批准開展用於治療膿毒症的II期臨床研究,這是集團在呼吸及重症抗感染領域的又一次重大研發進展。
呼吸及重症抗感染領域為集團核心戰略領域之一,STC3141為全新作用機制的全球創新產品,通過中和胞外組蛋白和中性粒細胞誘捕網來逆轉機體過度免疫反應造成的器官損傷,可用於多種重症適應症,如膿毒症和ARDS等臨床上死亡率高且缺乏特異性治療藥物的疾病。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.